CRIS Current Research Information System

STEFONI, VITTORIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.244
EU - Europa 3.664
AS - Asia 2.219
AF - Africa 256
SA - Sud America 20
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 11.412
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.207
GB - Regno Unito 831
SE - Svezia 771
CN - Cina 686
IT - Italia 677
VN - Vietnam 642
SG - Singapore 542
DE - Germania 486
IN - India 190
IE - Irlanda 167
UA - Ucraina 159
FR - Francia 133
RU - Federazione Russa 133
TG - Togo 93
JO - Giordania 59
ZA - Sudafrica 58
EE - Estonia 57
CI - Costa d'Avorio 56
FI - Finlandia 49
HR - Croazia 49
NG - Nigeria 40
CA - Canada 34
BE - Belgio 32
CH - Svizzera 29
IR - Iran 21
PL - Polonia 20
HK - Hong Kong 16
ID - Indonesia 16
BG - Bulgaria 15
JP - Giappone 15
NL - Olanda 14
ES - Italia 13
BR - Brasile 12
SC - Seychelles 9
AT - Austria 7
LB - Libano 7
RO - Romania 6
MY - Malesia 5
TR - Turchia 5
UZ - Uzbekistan 5
IL - Israele 4
AU - Australia 3
LT - Lituania 3
MX - Messico 3
NZ - Nuova Zelanda 3
PE - Perù 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AR - Argentina 2
BN - Brunei Darussalam 2
CL - Cile 2
CZ - Repubblica Ceca 2
GR - Grecia 2
NO - Norvegia 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
BY - Bielorussia 1
DK - Danimarca 1
EC - Ecuador 1
EU - Europa 1
HU - Ungheria 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
OM - Oman 1
PH - Filippine 1
Totale 11.412
Salva come PNG Salva come JPEG
Città #
Southend 744
Fairfield 624
Chandler 508
Singapore 475
Ashburn 377
Houston 321
Santa Clara 314
Woodbridge 314
Seattle 274
Ann Arbor 269
Wilmington 256
Dong Ket 255
Cambridge 220
Princeton 206
Dublin 167
Boardman 151
Bologna 99
Jacksonville 99
Lomé 93
Berlin 88
Nanjing 78
Westminster 78
New York 68
Padova 64
Amman 59
Abidjan 56
Bremen 53
Turin 52
Jinan 51
Beijing 47
Helsinki 47
Milan 45
Shenyang 42
Rome 41
Abeokuta 39
San Diego 35
Los Angeles 31
Saint Petersburg 31
Redwood City 29
Jiaxing 28
Changsha 26
Nanchang 26
Brussels 25
Florence 25
Zhengzhou 25
Dearborn 24
Hebei 22
Toronto 22
Bern 21
Des Moines 20
Falls Church 19
Hyderabad 19
Hangzhou 18
Tianjin 18
Guangzhou 16
Redmond 16
Jakarta 15
Mülheim 15
Taizhou 14
Warsaw 14
Olalla 13
Tokyo 13
Falkenstein 12
Sofia 12
Taiyuan 12
Modena 11
Zanjan 11
Catania 10
Hong Kong 10
Phoenix 10
Shanghai 10
Norwalk 9
Bühl 8
London 8
Mahé 8
Monmouth Junction 8
Paris 8
Reggio Emilia 8
Rijeka 8
Verona 8
Wayne 8
Frankfurt am Main 7
Haikou 7
Ningbo 7
San Francisco 7
Vienna 7
Andover 6
Casalecchio di Reno 6
Kunming 6
Medford 6
São Paulo 6
Wuhan 6
Buffalo 5
Chengdu 5
Dallas 5
Falconara Marittima 5
Foshan 5
Ottawa 5
Parma 5
Shenzhen 5
Totale 7.544
Salva come PNG Salva come JPEG
Nome #
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 240
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 225
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 197
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 184
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 182
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 181
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 176
Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. 175
18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. 168
18 F-FDG PET in malignant lymphoma: significance of positive findings 167
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 164
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 155
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 154
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 153
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 153
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 153
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 151
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 150
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 150
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 145
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 145
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 144
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. 143
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 136
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 136
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 134
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 132
Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. 131
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 131
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial 130
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS 129
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. 129
Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET. 128
Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. 126
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 125
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 125
Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy. 125
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. 125
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 125
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 124
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 124
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 124
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 121
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 120
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 120
Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. 120
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 118
Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients 117
Late FDG PET normalization after radioimmunotherapy in a patient with non-Hodgkin lymphoma. 117
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 116
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 116
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 116
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. 116
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 115
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 115
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 115
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 111
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 111
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 110
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. 109
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 107
Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. 105
FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma. 103
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 101
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). 101
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 101
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial 99
Rituximab in primary conjunctiva lymphoma. 97
Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience 96
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. 96
Chronic lymphocytic leukemia focus in the context of a cardiac mass in a pretreated patient: an exceptional incidental finding 96
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 94
FDG-PET in the serial assessment of patinets with lymphoma in complete remission 92
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. 91
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 91
Clinical significance of axillary findings in patients with lymphoma during follow up. C 89
Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine 88
Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis 88
Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. 87
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 87
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 78
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience 77
Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma 73
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi 66
Finalization of autologous stem cell transplant in complex and multirelapsed follicular lymphoma 66
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 64
Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience 63
null 63
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 62
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 59
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy 57
Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience. 49
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 48
Intravascular Large B-cell Lymphoma Successfully Treated with Autologous Transplantation 48
Diffuse large B cell lymphoma characteristics and outcomes during the COVID-19 pandemic in two tertiary centers - an Israeli/ Italian study 43
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 41
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 39
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 39
Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T-cell lymphoma: A FIL phase 2 study 38
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases 37
Totale 11.396
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.973
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.973
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.411 0 0 0 0 0 0 306 335 357 175 111 127
2020/20211.617 248 96 44 52 46 131 11 81 159 61 92 596
2021/20222.113 310 54 132 258 149 98 37 133 61 145 425 311
2022/20232.366 246 346 159 300 177 185 52 140 413 68 159 121
2023/2024744 62 112 57 93 59 106 48 44 26 53 33 51
2024/20251.713 136 417 259 205 502 185 9 0 0 0 0 0
Totale 11.700